Kylie Sproston

CEO at Bellberry Limited

Speaker

Kylie Sproston is the CEO of Bellberry Limited, a role she's held since early 2014. A Chartered Engineer, Ms Sproston has expertise across the full pharmaceutical product lifecycle, and has held key positions in both technical and management disciplines in the global Pharmaceutical and Biotech industries from research to global manufacturing and supply.

Ms Sproston is an experienced non-executive and company director, recently completing three terms as a ministerial appointment on the Cooperative Research Centres Advisory Committee, two of which as Chair, with oversight of the Commonwealth Government $1.5Bn programme. She is a Director of the Academy of Technological Sciences and Engineering.

Ms Sproston received an MEng (Hons) in Mechanical Engineering from Loughborough University (UK) and an MSc in Pharmaceutical Engineering Advanced Training from University of Manchester (UK). She is a Fellow of the Australian Academy of Technology and Engineering (ATSE); and a Foundation Fellow of ARCS Australia, the Australian professional society for the Medical, Pharmaceutical and Research sector. She is a Graduate of the Australian Institute of Company Directors (AICD) Company Directors Course. Kylie was awarded the 2021 ARCS Innovation Award for contributions to the Australian life sciences sector.

This year, Ms Sproston received the highest honour from Australian LifeSciences (formerly ARCs) with the 2026 Excellence Award, recognising her outstanding leadership and significant contribution to the MedTech and Pharmaceutical sectors. Under her stewardship, Bellberry has grown into an internationally recognised not-for-profit organisation advancing ethical research, participant protection, community engagement and innovation.